Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Annals of hematology·2026

Same author

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

HemaSphere·2026

Same author

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

Same author

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026

Same author

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026

Same author

Kenny-Caffey syndrome: nanophthalmos complicated by uveal effusion, presentation and treatment.

Retinal cases & brief reports·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results

Andrea Duminuco¹, Vittorio Del Fabro², Gabriella Santuccio¹

¹Hematology With BMT Unit, A.O.U. "G. Rodolico-San Marco", Catania, Italy.

European Journal of Haematology

|November 24, 2025

Summary

A new prognostic score (ME-IPS) using clinical and inflammatory indices identifies patients at high risk for refractory Hodgkin lymphoma (HL). This score, combined with PET-2 imaging, can improve treatment decisions for advanced HL.

Keywords:

Hodgkin lymphoma ME‐IPS PFS inflammatory indexes prognosis

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Related Experiment Videos

Last Updated: Jun 6, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Area of Science:

Hematology
Oncology
Clinical Prognostics

Background:

Identifying patients with relapsed/refractory Hodgkin lymphoma (R/R HL) is critical.
The International Prognostic System (IPS) has limitations in modern treatment contexts.
Interim PET-2 scans are valuable but available only after treatment initiation.

Purpose of the Study:

To investigate the prognostic role of peripheral blood inflammatory indices in Hodgkin lymphoma.
To develop a novel prognostic score for predicting R/R HL.
To compare the performance of the new score against the traditional IPS.

Main Methods:

Analysis of clinical and inflammatory indices in 212 Hodgkin lymphoma patients.
Focus on peripheral blood ratios, including SII (platelets × neutrophils/lymphocytes) and IgM levels.
Development and validation of the ME-IPS score based on identified risk factors.

Main Results:

The ME-IPS score incorporates SII, IgM, gender, and extranodal localization.
ME-IPS effectively stratifies patients into low, intermediate, and high-risk groups.
The ME-IPS demonstrated superior performance in identifying high-risk patients compared to the traditional IPS at diagnosis.

Conclusions:

The ME-IPS model offers a promising tool for early risk stratification in Hodgkin lymphoma.
Combining ME-IPS with PET-2 imaging may enhance prognostic accuracy for advanced disease.
This approach can aid in guiding clinical treatment decisions for Hodgkin lymphoma patients.